Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will be discussing 3Q20 financial results with the investment community.on 9th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.neurocrine.com
Earnings Expectation
Neurocrine Biosciences, Inc. is set to announce third quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, NBIX to report 3Q20 income of $ 0.22 per share. For the full year, analysts anticipate top line of $ 1129.36 million, while looking forward to income of $ 2.38 per share bottom line.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in womens health.
